ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2868

NK Cell Characterization in Patients with Systemic Lupus Erythematosus: Increased Frequency of Ki67+ NK Cells Associated with Disease Activity and Type I Interferon Signature

Kelly Hudspeth1, Shu Wang2, Jingya Wang2, Saifur Rahman2, Michael Smith2, Kerry Casey2, Geoffrey Stephens3, Miguel Sanjuan2, Autoimmunity Molecular Medicine group2, Zerai G. Manna4, Sarfaraz Hasni4, Rachel Ettinger5 and Richard Siegel6, 1Immunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Respiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, 3Respiratory, Inflammatory, and Autoimmune Diseases Research, Medimmune, LLC, Gaithersburg, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5Respiratory, Inflammation and Autoimmunity (RIA), MedImmune, LLC, Gaithersburg, MD, 6Immunoregulation Section, Autoimmunity Branch and Office of the Clinical Director National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: innate immunity, natural killer (NK) cells, renal disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder whose pathology appears to involve many immune cell types. While it is clear that autoantibody producing B cells as well as CD4+ T cell help are key contributors to disease, little is known regarding the role of innate lymphoid cells such as Natural Killer (NK) cells in the pathogenesis of SLE.

Methods: We have characterized the phenotype of NK cells by multicolor flow cytometry, proteomics and genomics arrays in a large cohort of patients with SLE.

Results: While the overall percentage of NK cells was similar or slightly decreased compared to healthy controls, a subset of patients displayed a high frequency of NK cells expressing the proliferation marker, Ki-67, which was not found in healthy donors. Only a moderate increase of Ki-67 was observed on other immune cell types such as total CD4+, CD8+ T cells or CD19+ B cells in the same donors. Increased NK cell expression of Ki-67 was found to correlate with clinical parameters. Interestingly, elevated frequencies of Ki67+ NK cells were highly associated with active nephritis. Proteomics analysis and auto-antibody arrays also revealed significant correlations between NK cell expression of Ki-67 and type I interferon (IFN) gene score as well as SLE associated auto-antibodies

Conclusion: These results will contribute to the understanding of the mechanistic role of NK cells in immune-mediated pathology of SLE.


Disclosure: K. Hudspeth, None; S. Wang, Medimmune, LLC, 1; J. Wang, MedImmune, LLC, 1; S. Rahman, MedImmune, LLC, 1; M. Smith, MedImmune, LLC, 1; K. Casey, MedImmune, LLC, 1; G. Stephens, AstraZeneca, 1; M. Sanjuan, MedImmune, LLC, 1; A. M. Medicine group, MedImmune, LLC, 1; Z. G. Manna, None; S. Hasni, None; R. Ettinger, MedImmune, LLC, 1; R. Siegel, None.

To cite this abstract in AMA style:

Hudspeth K, Wang S, Wang J, Rahman S, Smith M, Casey K, Stephens G, Sanjuan M, Medicine group AM, Manna ZG, Hasni S, Ettinger R, Siegel R. NK Cell Characterization in Patients with Systemic Lupus Erythematosus: Increased Frequency of Ki67+ NK Cells Associated with Disease Activity and Type I Interferon Signature [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/nk-cell-characterization-in-patients-with-systemic-lupus-erythematosus-increased-frequency-of-ki67-nk-cells-associated-with-disease-activity-and-type-i-interferon-signature/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nk-cell-characterization-in-patients-with-systemic-lupus-erythematosus-increased-frequency-of-ki67-nk-cells-associated-with-disease-activity-and-type-i-interferon-signature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology